Group 1 - Cyclo Therapeutics, Inc. reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of -50% [1] - The company posted revenues of $0.12 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 69.25%, with no year-over-year revenue growth [2] - Cyclo Therapeutics shares have declined approximately 26.4% since the beginning of the year, contrasting with the S&P 500's gain of 13.9% [3] Group 2 - The earnings outlook for Cyclo Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.15 on revenues of $0.4 million, and -$0.62 on revenues of $1.5 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8]
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates